Skip to content

Effect of low potential renal acid load diet intervention on urinary lithogenic parameters in recurrent calcium urolithiasis patients.

Effect of low potential renal acid load diet intervention on urinary lithogenic parameters in recurrent calcium urolithiasis patients

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071065
Enrollment
Unknown
Registered
2023-05-04
Start date
2023-05-04
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urolithiasis

Interventions

Low potential renal acid load(PRAL) diet:Low potential renal acid load (PRAL) diet: limit animal protein, increase vegetable and fruit intake, increase fluid intake. The low PRAL value is based on the
The Potassium Citrate group:Oral potassium citrate sustained-release tablets 2 tablets, twice a day, and usual diet.
The usual diet group:Usual diet (control group)

Sponsors

The Second Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: • Patients more than18 years old less than 60years old. • Recurrent urolithiasis patients, based on having a history of at least 2 episodes of stone formation diagnosed. (The stone formation was a twice new diagnosed kidney stone by urologist) • The stone composition confirmed as calcium oxalate. • Oral diet capability. • Not participating in other clinical research.

Exclusion criteria

Exclusion criteria: • Documented stone analysis with any calcium carbonate, magnesium ammonium phosphate, and calcium phosphate composition. • Systemic cause for stone disease (primary hyperparathyroidism, complete distal renal tubular acidosis, systemic acidosis, active urinary tract infection). • Concurrent medication therapy (potassium citrate, sodium citrate, sodium bicarbonate, diuretic, angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist, topiramate, acetazolamide). • Renal insufficiency (GFR <50ml/min/m2). • Elevated serum potassium level (= 4.5 mmol/L) or hyperkalemia. • Pregnancy. • Morbidity: gout, hyperuricemia, chronic diarrhea, insulin resistance, hyperparathyroidism, idiopathic hypercalcemia, hypertension, diabetes mellitus. • Complicated with infection, with or without antibiotic treatment. • Patients with active urinary tract infection • Previous gastrointestinal diseases or gastrointestinal surgery. • Mental patients or unable to cooperate for various reasons. • Patients with peptic ulcer disease. • Postoperative severe urinary infection or severe urinary infection. • Postoperative symptomatic patients. • Can not eat low PRAL diet. • Inability to obtain informed consent.

Design outcomes

Primary

MeasureTime frame
24-hour urine solute analysis (urine citric acid, urine potassium, uric oxalic acid, urine calcium, uric acid);

Countries

China

Contacts

Public ContactPei Li

The Second Affiliated Hospital of Kunming Medical University

peilinli@live.cn+86 15687171791

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026